<DOC>
	<DOCNO>NCT01592773</DOCNO>
	<brief_summary>The objective study evaluate long-term safety tolerability memantine treatment pediatric patient autism , Asperger 's Disorder Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS ) .</brief_summary>
	<brief_title>Safety Study Memantine Pediatric Patients With Autism , Asperger 's Disorder Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS )</brief_title>
	<detailed_description>This clinical study 48-week , multicenter , multinational , open-label extension study pediatric outpatient autism , Asperger 's Disorder , PDD-NOS conduct 106 study center . Patients eligible long-term extension study : - complete open-label Study MEM MD 67 , - complete open-label Study MEM-MD-91 , - complete double-blind Study MEM-MD-68 , - discontinue study MEM-MD-68 meeting requirement loss therapeutic response The weight-based dose limit study follow : Group A : â‰¥ 60 kg ; maximum 15 mg/day Group B : 40-59 kg ; maximum 9 mg/day Group C : 20-39 kg ; maximum 6 mg/day Group D : &lt; 20 kg ; maximum 3 mg/day The decision close study early base data 2 double-blind placebo-controlled study ( MEM-MD-57A MEM-MD-68 ) fail demonstrate statistically significant difference memantine placebo primary efficacy parameter base Social Responsiveness Scale ( SRS ) total raw score .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Patients complete Study MEMMD67 , MEMMD68 , MEMMD91 , discontinue Study MEMMD68 due meeting criterion loss therapeutic response . Having normal result physical examination laboratory test Visit 1 study ( last visit precede study ) . Any abnormal finding must deem clinically significant Investigator document . Have family sufficiently organize stable guarantee adequate safety monitor continuous attendance clinic visit duration study Patients discontinue precede memantine study due adverse event possibly relate study drug Patients concurrent medical condition might interfere conduct study , confound interpretation study result , endanger patient 's well Significant risk suicidality base Investigator 's judgment , Aberrant Behavior Checklistirritability subscale ( ABCI ) , appropriate , indicated response `` yes '' question 4 5 suicidal ideation section Children 's ColumbiaSuicide Severity Rating Scale ( CSSRS ) suicidal behavior</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Autistic Disorder</keyword>
	<keyword>Asperger 's Disorder</keyword>
	<keyword>Asperger 's</keyword>
	<keyword>Pediatric Autism</keyword>
	<keyword>Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS )</keyword>
	<keyword>Pervasive Child Development Disorder</keyword>
</DOC>